Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
University of Southern California/Norris Cancer Center
mi
from
Los Angeles, CA
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
University of Southern California/Norris Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
University of CA Los Angeles
mi
from
Los Angeles, CA
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
University of CA Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
St Mary's Medical Center
mi
from
San Francisco, CA
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
St Mary's Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
University of Colorado Cancer Center
mi
from
Aurora, CO
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Baptist Cancer Institute
mi
from
Jacksonville, FL
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Baptist Cancer Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Lakeland Regional Cancer Center
mi
from
Lakeland, FL
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Lakeland Regional Cancer Center
mi
from
Lakeland, FL
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
University of Miami Hospital and Clincs/SCCC
mi
from
Miami, FL
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
University of Miami Hospital and Clincs/SCCC
mi
from
Miami, FL
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Waren Billhartz Cancer Center
mi
from
Maryville, IL
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Waren Billhartz Cancer Center
mi
from
Maryville, IL
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
IA Blood and Cancer Care, PLC
mi
from
Cedar Rapids, IA
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
IA Blood and Cancer Care, PLC
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Univ of Minnesota
mi
from
Minneapolis, MN
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
St. John's Medical Research
mi
from
Springfield, MO
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
St. John's Medical Research
mi
from
Springfield, MO
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Saint Louis University
mi
from
St. Louis, MO
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Saint Louis University
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Atlantic Melanoma Center
mi
from
Morristown, NJ
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Atlantic Melanoma Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Piedmont Hematology
mi
from
Winston-Salem, NC
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Piedmont Hematology
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
OH State University Arthur G. James Cancer Hospital
mi
from
Columbus, OH
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
OH State University Arthur G. James Cancer Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Integris Cancer Institute of OK
mi
from
Oklahoma City, OK
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Integris Cancer Institute of OK
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Mary Crowley Research Center
mi
from
Dallas, TX
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Mary Crowley Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
University of TX - MD Anderson Cancer Center
mi
from
Houston, TX
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
University of TX - MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Univ of TX Med School at Houston
mi
from
Houston, TX
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Univ of TX Med School at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Covenant Health System DBA Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Covenant Health System DBA Joe Arrington Cancer Research and Treatment Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
University of Washington Medical Center, Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
University of Washington Medical Center, Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  7/31/2015
Port Macquarie Base Hospital
mi
from
Port Macquarie,
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
An Open-Label, Multicenter, Phase III Trial of ABI-007 vs Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 7/31/2015
Port Macquarie Base Hospital
mi
from
Port Macquarie,
Click here to add this to my saved trials
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Status: Enrolling
Updated:  8/4/2015
Rady Children's Hospital
mi
from
San Diego, CA
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Status: Enrolling
Updated: 8/4/2015
Rady Children's Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Status: Enrolling
Updated:  8/4/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Status: Enrolling
Updated: 8/4/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Status: Enrolling
Updated:  8/4/2015
The Children's Cancer Hospital at UT M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
Status: Enrolling
Updated: 8/4/2015
The Children's Cancer Hospital at UT M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Status: Enrolling
Updated:  8/5/2015
Beckman Laser Institute, Unversity of California Irvine
mi
from
Irvine, CA
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Status: Enrolling
Updated: 8/5/2015
Beckman Laser Institute, Unversity of California Irvine
mi
from
Irvine, CA
Click here to add this to my saved trials
A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions
A Pilot Study to Evaluate the Correlation Between Modified Two Layer Diffuse Optical Spectroscopy With the Clinical and Histological Examinations of Pigmented Skin Lesions Based on Physiological Parameters
Status: Enrolling
Updated:  8/5/2015
Beckman Laser Medical clinic, UCI
mi
from
Irvine, CA
A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions
A Pilot Study to Evaluate the Correlation Between Modified Two Layer Diffuse Optical Spectroscopy With the Clinical and Histological Examinations of Pigmented Skin Lesions Based on Physiological Parameters
Status: Enrolling
Updated: 8/5/2015
Beckman Laser Medical clinic, UCI
mi
from
Irvine, CA
Click here to add this to my saved trials
A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions
A Pilot Study to Evaluate the Correlation Between Modified Two Layer Diffuse Optical Spectroscopy With the Clinical and Histological Examinations of Pigmented Skin Lesions Based on Physiological Parameters
Status: Enrolling
Updated:  8/5/2015
UCIMC
mi
from
Orange, CA
A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions
A Pilot Study to Evaluate the Correlation Between Modified Two Layer Diffuse Optical Spectroscopy With the Clinical and Histological Examinations of Pigmented Skin Lesions Based on Physiological Parameters
Status: Enrolling
Updated: 8/5/2015
UCIMC
mi
from
Orange, CA
Click here to add this to my saved trials
Optimizing Photodynamic Therapy of Cutaneous Neoplastic Diseases Via Structured Illumination and Real-time Dosimetry.
Non-contact Imaging Device (Camera) Can Help Improve Treatment for Patients With Basal Cell Carcinoma.
Status: Enrolling
Updated:  8/5/2015
Beckman Laser Institute Medical clinic
mi
from
Irvine, CA
Optimizing Photodynamic Therapy of Cutaneous Neoplastic Diseases Via Structured Illumination and Real-time Dosimetry.
Non-contact Imaging Device (Camera) Can Help Improve Treatment for Patients With Basal Cell Carcinoma.
Status: Enrolling
Updated: 8/5/2015
Beckman Laser Institute Medical clinic
mi
from
Irvine, CA
Click here to add this to my saved trials
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
Evaluating Attenuation Correction Methods Applied to PET/MRI
Status: Enrolling
Updated:  8/12/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
Evaluating Attenuation Correction Methods Applied to PET/MRI
Status: Enrolling
Updated: 8/12/2015
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Video-Based Treatment Options for Basal Cell Carcinoma
The Efficiency and Effectiveness of Using Video-Based Treatment Option Education Medium for Basal Cell Carcinoma Patients
Status: Enrolling
Updated:  8/13/2015
Emory University
mi
from
Atlanta, GA
Video-Based Treatment Options for Basal Cell Carcinoma
The Efficiency and Effectiveness of Using Video-Based Treatment Option Education Medium for Basal Cell Carcinoma Patients
Status: Enrolling
Updated: 8/13/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Video-Based Treatment Options for Basal Cell Carcinoma
The Efficiency and Effectiveness of Using Video-Based Treatment Option Education Medium for Basal Cell Carcinoma Patients
Status: Enrolling
Updated:  8/13/2015
Atlanta VA Medical Center
mi
from
Decatur, GA
Video-Based Treatment Options for Basal Cell Carcinoma
The Efficiency and Effectiveness of Using Video-Based Treatment Option Education Medium for Basal Cell Carcinoma Patients
Status: Enrolling
Updated: 8/13/2015
Atlanta VA Medical Center
mi
from
Decatur, GA
Click here to add this to my saved trials
Vaccination Plus Ontak in Patients With Metastatic Melanoma
Randomized Phase II Study of Multipeptide Vaccination With or Without Regulatory T Cell Depletion Using Ontak in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  8/14/2015
University of Chicago
mi
from
Chicago, IL
Vaccination Plus Ontak in Patients With Metastatic Melanoma
Randomized Phase II Study of Multipeptide Vaccination With or Without Regulatory T Cell Depletion Using Ontak in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 8/14/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated:  8/20/2015
The Institute for Drug Development
mi
from
San Antonio, TX
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated: 8/20/2015
The Institute for Drug Development
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated:  8/20/2015
South Texas Accelerated
mi
from
San Antonio, TX
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated: 8/20/2015
South Texas Accelerated
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated:  8/20/2015
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Phase II: An Open-Label Extension Study of 168-Hour Continuous Infusion of YM155 in Subjects Previously Enrolled in a Phase I or Phase II Protocol Administering YM155
Status: Enrolling
Updated: 8/20/2015
Huntsman Cancer Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
University of South Alabama
mi
from
Mobile, AL
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
University of South Alabama
mi
from
Mobile, AL
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
Arizona Clinical Research Center
mi
from
Tuscon, AZ
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
Arizona Clinical Research Center
mi
from
Tuscon, AZ
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
The Angeles Clinic and Research
mi
from
Los Angeles, CA
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
The Angeles Clinic and Research
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
UCLA
mi
from
Los Angeles, CA
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
Redwood Regional Medical Group
mi
from
Sebastopol, CA
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
Redwood Regional Medical Group
mi
from
Sebastopol, CA
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
University of Colorado
mi
from
Aurora, CO
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
St. Luke's Hospital Cancer Center
mi
from
Bethlehem, PA
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
St. Luke's Hospital Cancer Center
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated:  8/20/2015
London Regional Cancer Centre
mi
from
London,
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
A Phase II, Multicenter, Open-Label Study Of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
Status: Enrolling
Updated: 8/20/2015
London Regional Cancer Centre
mi
from
London,
Click here to add this to my saved trials
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients With Unresectable Stage III or Stage IV Melanoma Disease
Status: Enrolling
Updated:  8/27/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients With Unresectable Stage III or Stage IV Melanoma Disease
Status: Enrolling
Updated: 8/27/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer: Potential for Informative Biomarkers and Therapeutic Targets
Status: Enrolling
Updated:  8/28/2015
Beckman Laser Institute
mi
from
Irvine, CA
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer
Role of Metabolic Enzymes in Non-Melanoma Skin Cancer: Potential for Informative Biomarkers and Therapeutic Targets
Status: Enrolling
Updated: 8/28/2015
Beckman Laser Institute
mi
from
Irvine, CA
Click here to add this to my saved trials